Could one year of immunotherapy be enough for advanced melanoma?
NCT ID NCT07376317
First seen Feb 02, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study looks at whether giving the immunotherapy drug pembrolizumab for one year works just as well as the usual two-year course for people with advanced melanoma that has spread. The trial involves 29 adults in Brazil whose melanoma cannot be removed by surgery or cured. The goal is to see if a shorter treatment can control the disease without reducing its effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ICESP
São Paulo, São Paulo, 01246000, Brazil
Conditions
Explore the condition pages connected to this study.